Home Cart Sign in  
Chemical Structure| 2381037-82-5 Chemical Structure| 2381037-82-5

Structure of RBN-2397
CAS No.: 2381037-82-5

Chemical Structure| 2381037-82-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

RBN-2397 is a potent, accross species and orally active NAD+ competitive inhibitor of PARP7 (IC50<3 nM). RBN-2397 selectively binds to PARP7 (Kd=0.001 μM) and restores IFN signaling. RBN-2397 has the potential for the study of advanced or metastatic solid tumors .

Synonyms: Atamparib

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Enbergs, Noah ; Halabi, Elias A. ; Goubet, Anne-Gaelle ; Schleyer, Kelton ; Fredrich, Ina R. ; Kohler, Rainer H. , et al.

Abstract: Tumor-associated macrophages (TAM) are a diverse population of myeloid cells that are often abundant and immunosuppressive in human cancers. CXCL9Hi TAM has recently been described to have an antitumor phenotype and is linked to immune checkpoint response. Despite the emerging understanding of the unique antitumor TAM phenotype, there is a lack of TAM-specific therapeutics to exploit this new biological understanding. Here, the discovery and characterization of multiple small-molecule enhancers of chemokine ligand 9 (CXCL9) and their targeted delivery in a TAM-avid systemic nanoformulation is reported. With this strategy, it is efficient encapsulation and release of multiple drug loads that can efficiently induce CXCL9 expression in macrophages, both in vitro and in vivo in a mouse . These observations provide a window into the molecular features that define TAM-specific states, an insight a novel therapeutic anticancer approach is used to discover.

Keywords: CXCL9 ; IFNg ; PARP7 ; STING ; macrophage ; nanoparticles ; polarization

Purchased from AmBeed:

Alternative Products

Product Details of RBN-2397

CAS No. :2381037-82-5
Formula : C20H23F6N7O3
M.W : 523.43
SMILES Code : O=C1C(C(F)(F)F)=C(N[C@@H](C)COCCC(N2CCN(C3=NC=C(C(F)(F)F)C=N3)CC2)=O)C=NN1
Synonyms :
Atamparib
MDL No. :MFCD32701939
InChI Key :UQZCQKXJAXKZQH-LBPRGKRZSA-N
Pubchem ID :146047148

Safety of RBN-2397

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of RBN-2397

epigenetics
DNA

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT04053673 Solid Tumor, Adult PHASE1 UNKNOWN 2023-07-31 University of Colorado Anschut... More >>z Medical Campus, Aurora, Colorado, 80045, United States|SCRI-Denver/HealthOne, Denver, Colorado, 80218, United States|Yale Cancer Center, Yale University, New Haven, Connecticut, 06520, United States|Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando, Florida, 32827, United States|SCRI-Sarasota/Florida Cancer Specialists, Sarasota, Florida, 34232, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Washington University, Saint Louis, Missouri, 63110, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, 15213, United States|SCRI-Nashville/Tennessee Oncology, Nashville, Tennessee, 37203, United States|MD Anderson Cancer Center, Houston, Texas, 77030-4009, United States|Hospital Quironsalud Barcelona - NEXT Oncology, Barcelona, 08023, Spain|Vall d'Hebron, Barcelona, 08035, Spain|Hospital Quironsalud Madrid - NEXT Oncology, Madrid, 28223, Spain|Hospital Clinic Universitario Biomedical Research institute INCLIVA, Valencia, Spain Less <<
NCT05127590 Advanced Squamous Non-Small Ce... More >>ll Lung Carcinoma Less << PHASE1|PHASE2 ACTIVE_NOT_RECRUITING 2025-12-23 Helen F. Graham Cancer Center ... More >>(Christiana Care), Newark, Delaware, 19713, United States|Cancer Treatment Centers of America, Newnan, Georgia, 30265, United States|Hematology and Oncology Clinic, Baton Rouge, Louisiana, 70809, United States|Sarah Cannon Research Institute, Nashville, Tennessee, 37203, United States|Rambam Care Campus, Haifa, Israel|Hadassah Medical Center, Jerusalem, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Hospital Clinico Universitario De Santiago De Compostela, A Coru?a, Spain|NEXT Oncology Barcelona, Barcelona, Spain|Vall D'Hebron Insitute of Oncology, Barcelona, Spain|Hospital Universitario Ramon Y Cajal, Madrid, Spain|Hospital Regional Universitario de Malaga, Málaga, Spain|Hospital Quiron Madrid, Pozuelo de Alarcón, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|INCLIVA Biomedical Research Institute, Valencia, Spain|Beatson West of Scotland Cancer Centre, Glasgow, Scotland, United Kingdom|Imperial College London, London, United Kingdom|Sarah Cannon Research Institute UK (University College London Hospitals), London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.91mL

0.38mL

0.19mL

9.55mL

1.91mL

0.96mL

19.10mL

3.82mL

1.91mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories